Navigation Links
SEQUEL Trial Results for Qnexa® Published in AJCN Show 10% Sustained Weight Loss Over 2 Years
Date:12/8/2011

MOUNTAIN VIEW, Calif., Dec. 8, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that results from the SEQUEL study were published in The American Journal of Clinical Nutrition, a peer-reviewed journal with broad, multidisciplinary readership. The SEQUEL study evaluated the long-term efficacy and safety of Qnexa in 676 overweight and obese subjects with cardiometabolic disease. In addition to 10% sustained weight loss, the study also found that significantly more placebo patients became diabetic over the two years as compared to patients treated with Qnexa. The data suggest that Qnexa, in conjunction with lifestyle modification, may provide a well-tolerated and effective option for the sustained treatment of obesity and the potential to prevent many in this population from progressing to type 2 diabetes.

"Recent data show that diabetes, like obesity, has become a rapidly growing epidemic, with nearly 1 in 10 adults potentially affected by the disease," said lead investigator W. Timothy Garvey M.D., director of the Nutrition Obesity Research Center, University of Alabama at Birmingham. "Results from the SEQUEL study underscore Qnexa's potential as a non-surgical option for sustained weight loss and improvements in comorbidities in overweight and obese patients."

Specific results as published in AJCN are as follows:

  • Patients treated with Qnexa had significant, sustained weight loss compared to those in the placebo group over two years. 
  • Average weight loss at week 108 was -9.3% and -10.5%, respectively, for the mid- and top-dose as compared to -1.8% for the placebo group (least-squares mean ITT-LOCF).
  • Qnexa patients had improved cardiovascular and metabolic risk factors and a decrease in the need for associated medications in comparison with the placebo group.
  • Placebo patients had a three times greater li
    '/>"/>

  • SOURCE VIVUS, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Additional Analysis from Two-Year Sequel Study of QNEXA Featured at The 2011 Annual Scientific Meeting of The Obesity Society
    2. Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting
    3. SequelMed EMR Version 8 Certified by Ohio Board of Pharmacy
    4. Sequel Systems, Inc. Meaningful Use EHR Receives ONC-ATCB 2011/2012 Certification
    5. Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology
    6. Sequella Receives American Recovery and Reinvestment Funding Through the NIH
    7. Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
    8. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
    9. TIs new MSP430™ microcontrollers enable more performance and higher precision in home automation, industrial and portable medical applications
    10. GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market
    11. GiiResearch.com: Insulin Pumps - Availability of Reimbursement and Favorable Clinical Trial Data to Drive Market Growth
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
    (Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Insulin ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong ...
    (Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
    Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
    ... , , , CARLSBAD, Calif., ... today its intention to file a Special Protocol Assessment (SPA) with ... on its lead drug, DCCR, for the treatment of very high ... primary efficacy endpoint assessed at 12 weeks. This decision followed ...
    ... , , , ... ANDS ) today announced viral load data for the final cohort of ... Company,s oral inducer of endogenous interferons that acts via the toll-like receptor ... other day over 10 days, the mean (+/-SEM) maximal decline in viral ...
    Cached Medicine Technology:Essentialis to Submit SPA for Hypertriglyceridemia 2ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients 2ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients 3ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients 4ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients 5
    (Date:4/24/2014)... On April 28, the Center for BrainHealth will ... our most pressing brain-related challenges at its inaugural ... Resilience and Regeneration." Featured speakers will include Dr. ... the Center for BrainHealth, U.S. Senator Chuck Grassley ... Doggett, Deputy Assistant Secretary for Policy and Early ...
    (Date:4/24/2014)... more than one out of three survivors of ... in The Lancet Respiratory Medicine , and ... rather than mentally. , It is one of ... and functional outcomes of critical care survivors, according ... of Medicine, and it highlights a significant public ...
    (Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
    (Date:4/23/2014)... 24, 2014 Pregnant immigrants from Sub-Saharan Africa, ... monitoring during pregnancy, according to new research from ... in the British Journal of Obstetrics and ... eclampsia rates among immigrants and native-born women in ... Denmark, Sweden, Spain (Catalonia and Valencia) and the ...
    (Date:4/23/2014)... April 23, 2014 The American Society for Radiation ... Role of Postoperative Radiation Therapy for Endometrial Cancer: ... of adjuvant radiation therapy in the treatment of ... in the May-June 2014 issue of Practical ... journal of ASTRO. The full-length guideline is available ...
    Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3
    ... are readmitted within a year, study finds , , WEDNESDAY, ... patients discharged from the hospital is readmitted within 30 ... within a year, a new study finds. , The ... problem that researchers believe could be prevented through better ...
    ... Extreme Physical Performance (EP2), a sport supplement firm, has ... that manufactures a new generation of safe and effective ... human physical performance. Together, they will bring innovative new ... gym goers. TORABOLIC is Indus,s first new novel ingredient ...
    ... YORK, April 1 Spring may be synonymous ... for Alex Mele of Coram, NY, a 15-year-old baseball player ... a fight to shut out cancer.Mele, a catcher and third ... Junior Varsity Baseball Team, suddenly fell ill last November. ...
    ... SAN DIEGO, April 1 Gen-Probe (Nasdaq: ... its co-respondents F. Hoffmann-La Roche Ltd. and Roche Molecular ... (now Qiagen) concerning the Company,s supply and purchase agreement ... , Earlier today, a three-member arbitration panel ...
    ... Touch(TM) hearing aid is smallest receiver-in-canal product availableSALT LAKE ... SNCI ) will celebrate its first receiver-in-canal ("RIC") ... be held in Dallas, Texas, April 2 through 4, ... is the smallest receiver-in-canal product available in the market. ...
    ... 1 Novavax Inc. (Nasdaq: NVAX) announced ... of 12.5 million shares of Novavax,s common stock at $0.88 per ... of the new strategic alliance between Novavax and Cadila. Novavax intends ... to pay a portion of its 4.75% senior convertible notes due ...
    Cached Medicine News:Health News:High Rate of Rehospitalizations Costing Billions 2Health News:High Rate of Rehospitalizations Costing Billions 3Health News:New Sports Supplement Company to Partner with Indus Biotech 2Health News:Blood, Marrow Drive Offers Hope for Baseball Player, 15 2Health News:Gen-Probe, Roche Prevail in Arbitration With Digene Concerning Human Papillomavirus Agreement 2Health News:Gen-Probe, Roche Prevail in Arbitration With Digene Concerning Human Papillomavirus Agreement 3Health News:Sonic Innovations Celebrates Company's First Receiver-In-Canal Hearing Aid 2Health News:Sonic Innovations Celebrates Company's First Receiver-In-Canal Hearing Aid 3Health News:Novavax Announces Closing of $11 Million Common Stock Sale to Subsidiary of Cadila Pharmaceuticals 2
    ... proven to be a successful alternative ... knee arthroplasty with proper indications. The ... unicompartmental knee system developed to streamline ... latest conservative surgical techniques with the ...
    ... Knee CR system was designed to ... femoral joint has a recessed, deepened ... advancement of the patella, which has ... The anatomic groove promotes more normal ...
    The Biopro Modular TKO implant is among the thinnest bone conserving Posterior Cruciate Ligament sparing knees available. It provides all the benefits of the Biopro TKO implant and gives the option o...
    ... PowerSuite™ holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
    Medicine Products: